dacarbazine and Cytokine Release Syndrome

dacarbazine has been researched along with Cytokine Release Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Abdullah, SE; Baurain, JF; Butler, MO; Carvajal, RD; Curti, B; Demidov, L; Dummer, R; Gastaud, L; Goodall, H; Hamid, O; Hassel, JC; Holland, C; Joshua, AM; Kirkwood, JM; Mauch, C; Milhem, M; Nathan, P; Ochsenreither, S; Orloff, M; Piperno-Neumann, S; Piulats, JM; Rutkowski, P; Sacco, JJ; Salama, AKS; Schlaak, M; Shoushtari, AN; Sullivan, RJ; Yushak, M	1

Trials

1 trial(s) available for dacarbazine and Cytokine Release Syndrome

Article	Year
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. The New England journal of medicine, 2021, 09-23, Volume: 385, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cytokine Release Syndrome; Dacarbazine; Exanthema; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Recombinant Fusion Proteins; Survival Analysis; Uveal Neoplasms	2021

Article

Year

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

The New England journal of medicine, 2021, 09-23, Volume: 385, Issue:13

Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cytokine Release Syndrome; Dacarbazine; Exanthema; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Recombinant Fusion Proteins; Survival Analysis; Uveal Neoplasms

2021